DHL taps Southeast Asia growth with CRYOPDP deal
18 Apr 20253 min read
Summary
- DHL Supply Chain has acquired CRYOPDP, a leading biopharma courier, to strengthen its presence in Southeast Asia’s fast-growing life sciences market. The move expands DHL’s Pharma Specialized Network across key hubs such as Singapore and the Philippines, enhancing logistics for clinical trials and advanced therapies.
- By integrating CRYOPDP’s white-glove services with DHL Express and DHL Global Forwarding, the company aims to deliver seamless, end-to-end healthcare logistics. The partnership with Cryoport Inc. further enables hybrid solutions that meet strict regulatory and time-critical delivery needs.
- The acquisition positions DHL at the forefront of Southeast Asia’s healthcare logistics transformation, particularly in the high-growth cell and gene therapy segment. It underscores DHL’s strategy to lead in next-generation, patient-centric supply chain solutions across the region.
As Southeast Asia emerges as a vital node in the global life sciences ecosystem, DHL Supply Chain is strengthening its position with a move that goes beyond acquisition—it’s a clear signal of intent. The logistics giant’s purchase of CRYOPDP, a leading specialty courier for biopharma, clinical trials, and cell and gene therapies, is more than a growth play—it's a strategic leap forward to lead in the next era of healthcare logistics.
Backed by a deepened partnership with Cryoport, Inc., this acquisition sharpens DHL’s capabilities across Asia-Pacific. But it is Southeast Asia, in particular, that stands to gain the most. Value Chain Asia speaks exclusively to Edwin Wong, CEO of DHL Supply Chain Southeast Asia.
Expanding the Regional Footprint
CRYOPDP’s operational network spans 15 countries, including key APAC markets. In Southeast Asia, its presence in Singapore and the Philippines is set to reshape how life sciences supply chains operate in the region.CRYOPDP operates facilities across Asia-Pacific, including India, South Korea, Japan, Singapore, and the Philippines.
“
“In Southeast Asia, its presence in Singapore, a biopharma hub, and the Philippines, an emerging healthcare market, strengthens our Life Sciences & Healthcare capabilities in these key growth markets.”
The acquisition fits squarely into DHL’s plan to bolster its Pharma Specialized Network across Southeast Asia, enabling the company to deliver solutions that are both technically robust and tailored to complex market demands.
“
“The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network across Southeast Asia’s dynamic healthcare markets. With CRYOPDP’s established presence in Singapore and the Philippines – two of ASEAN's fastest-growing life sciences hubs – we are now better positioned to serve the evolving needs of clinical trials, biopharma, and cell & gene therapies, while strengthening our conventional pharma and life science healthcare capabilities.”
Integrated, End-to-End Solutions for Next-Gen Healthcare
By combining CRYOPDP’s white-glove courier model with the global reach of DHL Express and DHL Global Forwarding, the company is setting the stage for a new era of end-to-end, hybrid logistics solutions for healthcare.
“
“By combining CRYOPDP’s expertise with our extended partnership with Cryoport Inc., we can deliver fully integrated end-to-end solutions that enhance both our service capabilities and market position,” Wong explained. “This includes developing hybrid solutions that merge CRYOPDP’s specialized courier services with the global air capabilities of DHL Express and DHL Global Forwarding – significantly boosting our competitiveness in Southeast Asia’s growing life sciences healthcare market.”
One of the most transformative aspects of the partnership is DHL’s enhanced ability to serve the cell and gene therapy segment—a market segment that demands high precision, compliance, and speed.
“
"Our extended partnership with Cryoport Inc. will also enable us to develop differentiated, integrated services specifically for the cell and gene therapy sector. Together, these strategic initiatives solidify DHL Supply Chain as the preferred partner for life sciences companies navigating Southeast Asia’s complex and rapidly evolving markets.” Wong shared.
DHL’s acquisition of CRYOPDP isn’t just a business expansion—it’s a statement. It reflects DHL’s commitment to redefining healthcare logistics in Southeast Asia, and capitalizing on the region’s growing prominence in clinical research, pharmaceutical manufacturing, and biotech innovation.
As life sciences companies seek more agile, reliable, and patient-centric supply chains, DHL—with its expanded capabilities and strategic partnerships—is poised to deliver.
Southeast Asia’s life sciences sector is evolving fast—and now, its logistics backbone is evolving with it.